Clinical Trial Update: A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of abemaciclib (LY2835219) alone or with other agents in previously treated pancreatic ductal adenocarcinoma has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-25